Cullinan Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 16.36, 42.82, 31.44, 91.85, 228.55 ], "ebit_estimate": [ -214.44, -212.48, -277.37, -301.02, -212.58 ], "ebitda_estimate": [ -176.96, -214.73, -280.42, null, null ], "net_income_estimate": [ -197.77, -183.79, -258.04, -293.47, -206.8 ], "per_share_eps_estimate": [ -3.29, -2.4, -3.04, -2.97, -1.71 ], "eps_nri_estimate": [ -3.08, -2.46, -3.08, -2.97, -1.71 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 5.76, 5.25, 5.68, null, null ], "pretax_income_estimate": [ -202.12, -213.88, -265.35, -295.82, -255.03 ], "operating_cash_flow_per_share_estimate": [ -2.48, -1.47, -2.48, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -38.34, -47.11, -60.95, null, null ], "gross_margin_estimate": [ null, null, null, 9, 9 ], "operating_cash_flow_estimate": [ -149.95, -88.88, -149.95, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -6.4, "future_book_value_per_share_estimate_growth": -6.08, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -12.55, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ null, null, 16.16, 15, null, 1.38, 52.39, null ], "ebit_estimate": [ -57.06, -59.26, -44.73, -46.42, -59.3, -60.5, 38.3, null ], "ebitda_estimate": [ -56.86, -60.25, 10.85, -64.7, null, null, null, null ], "net_income_estimate": [ -52.94, -55.15, -40.86, -42.22, -57.07, -58.75, 39.53, null ], "per_share_eps_estimate": [ -0.86, -0.87, -0.73, -0.56, -0.87, -0.89, -0.43, null ], "eps_nri_estimate": [ -0.81, -0.86, -0.61, -0.64, -0.78, -0.86, -0.57, -0.88 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -54.38, -56.61, -40.69, -58.72, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ -0.74, -0.8, -0.21, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ -52.8, -62.63, 22.96, -71.06, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ -44.74, -48.37, -12.7, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -6.4, "future_book_value_per_share_estimate_growth": -6.08, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -12.55, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }